Literature DB >> 12653322

Owners' assessments of their dog's quality of life during palliative chemotherapy for lymphoma.

R J Mellanby1, M E Herrtage, J M Dobson.   

Abstract

The owners of 25 dogs with multicentric lymphoma which were treated by multidrug chemotherapy were interviewed to assess the quality of their pet's life during treatment. Sixty-eight per cent of the owners considered their dog's quality of life to be the same as before the lymphoma occurred, and the remaining 32 per cent felt that their pet's quality of life on chemotherapy treatment was acceptable but poorer than before the lymphoma occurred. Treatment complications were reported by 52 per cent of owners. Ninety-two per cent of owners had no regrets about treating their dog with multidrug chemotherapy. The results suggest that, while many dogs developed treatment complications during multidrug chemotherapy, most owners felt that the quality of life of their pets was good during treatment and had no regrets about opting for palliative chemotherapy.

Entities:  

Mesh:

Year:  2003        PMID: 12653322     DOI: 10.1111/j.1748-5827.2003.tb00127.x

Source DB:  PubMed          Journal:  J Small Anim Pract        ISSN: 0022-4510            Impact factor:   1.522


  9 in total

1.  Impact of Pretreatment Neutrophil Count on Chemotherapy Administration and Toxicity in Dogs with Lymphoma Treated with CHOP Chemotherapy.

Authors:  Q Fournier; J-C Serra; I Handel; J Lawrence
Journal:  J Vet Intern Med       Date:  2017-12-04       Impact factor: 3.333

2.  Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma.

Authors:  D H Thamm; D M Vail; G S Post; T M Fan; B S Phillips; S Axiak-Bechtel; R S Elmslie; M K Klein; D A Ruslander
Journal:  J Vet Intern Med       Date:  2017-04-03       Impact factor: 3.333

3.  Health-related quality of life in dogs treated with electrochemotherapy and/or interleukin-12 gene electrotransfer.

Authors:  Nina Milevoj; Natasa Tozon; Sabina Licen; Ursa Lampreht Tratar; Gregor Sersa; Maja Cemazar
Journal:  Vet Med Sci       Date:  2020-01-07

4.  Quality of life assessment in cancer patients receiving single-agent versus multidrug chemotherapy protocols.

Authors:  Marco Luigi Bianchi; Dario Drudi; Elisabetta Treggiari; Chiara Catalucci; Valeria Attorri; Irene Bonazzi; Paola Valenti
Journal:  Open Vet J       Date:  2021-12-05

5.  Vincristine chemotherapy trials and pharmacokinetics in tasmanian devils with tasmanian devil facial tumor disease.

Authors:  David N Phalen; Angela Frimberger; Stephen Pyecroft; Sarah Peck; Colette Harmsen; Suzanneth Lola; Beatriz de Mello Mattos; Kong M Li; Andrew J McLachlan; Antony Moore
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

Review 6.  Quality of life measurement in prospective studies of cancer treatments in dogs and cats.

Authors:  M A Giuffrida; S M Kerrigan
Journal:  J Vet Intern Med       Date:  2014-10-10       Impact factor: 3.333

7.  Mutation of p53 Gene and Its Correlation with the Clinical Outcome in Dogs with Lymphoma.

Authors:  A Koshino; Y Goto-Koshino; A Setoguchi; K Ohno; H Tsujimoto
Journal:  J Vet Intern Med       Date:  2015-12-17       Impact factor: 3.333

8.  Detection of circulating tumor cells using GeneScan analysis for antigen receptor gene rearrangements in canine lymphoma patients.

Authors:  Saaya Hiyoshi-Kanemoto; Yuko Goto-Koshino; Kenjiro Fukushima; Masashi Takahashi; Hideyuki Kanemoto; Kazuyuki Uchida; Yasuhito Fujino; Koichi Ohno; Hajime Tsujimoto
Journal:  J Vet Med Sci       Date:  2016-02-18       Impact factor: 1.267

9.  Clinical and histopathological evaluation of 16 dogs with T-zone lymphoma.

Authors:  Noriyuki Mizutani; Yuko Goto-Koshino; Masashi Takahashi; Kazuyuki Uchida; Hajime Tsujimoto
Journal:  J Vet Med Sci       Date:  2016-04-21       Impact factor: 1.267

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.